InsidersTradesSigma
현대바이오: directors' dealings · South Korea · DART (FSS)
DART:company-a838c0KR·DART (FSS)Mcap 1054.5Bn€Healthcare
Explore the full insider trade history of 현대바이오, a listed issuer based in South Korea. Shares are quoted on KR KR, under the supervision of DART (FSS). Operating in the Healthcare sector, 현대바이오 has published 4 insider filings. Market capitalisation: €1,054.5bn. The latest transaction was disclosed on 23 April 2026 — Other. Among the most active insiders: 씨앤팜. The full history is free.
4
Insider Decl.
0
Thresholds
·
1 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
10980.00 €
Analyst consensus
Income statement
Revenue3.52 Bn€
Gross profit243.6 M€7% margin
Net income−22.13 Bn€-629.1% margin
Valuation
Beta0.93
Balance sheet & cash
Market cap1054.50 Bn€
Total debt17.78 Bn€
Free Cash Flow−37.24 Bn€
Debt / Equity16%
Profitability & ownership
ROE-29.4%
ROA-11.4%
% insiders10.2%
% institutions6.6%
Last declaration on 23 April 2026
Declarations0 total
No declarations found
0 of 0 declarations